Q32 Bio Inc. (QTTB)
QTTB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1661998/000119312526099339/0001193125-26-099339-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | QTTB on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001661998 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $53.7M |
| Net income | $29.8M |
| Operating income | $16.9M |
| Net margin | 55.5% |
| Operating margin | 31.5% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $48.3M |
| Total assets | $61.8M |
| P/E (computed) | 8.3× |
| P/S (computed) | 4.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "Liquidity and Going Concern In accordance with the Financial Accounting Standards Board ( FASB ) Accounting Standards Update ( ASU ) 2014-15, Disclosure of Uncertainties about an Entity's ability to Continue as a Going Concern (Subtopic 205-40) , the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a goi" | 10-Q 2026-11-04 |
| Cash and burn | $289.6M cash; operating cash flow -$5.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 29,923,882 (2026-10-31); 12,304,352 a year earlier; 57,934,332 three years earlier. 3y figure adjusted for split (1-for-18 overall). | Cover page 2026-10-31 |
| Reverse splits, 3 years | 1; latest 1-for-18 on 2024-03-26 | Source 2024-03-26 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 5 424B5 takedowns, 5 at the market | Latest 2026-07-15 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $15.0M, sold $460K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$8.9M | -$4.4M | $289.6M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | Not filed | -$8.9M | -$3.1M | $106.3M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q1 2026 2026-03-31 | Not filed | -$7.6M | -$6.3M | $50.8M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q4 2025 2025-12-31 | Not filed | $57.7M | -$6.2M | $48.3M | No debt tags | $53.7M | 10-K 2026-03-10 |
| Q3 2025 2025-09-30 | Not filed | -$7.4M | -$4.2M | $49.0M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | Not filed | -$9.5M | -$10.7M | $54.8M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q1 2025 2025-03-31 | Not filed | -$11.0M | -$12.5M | $65.5M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q4 2024 2024-12-31 | $0 | -$14.2M | -$11.4M | $78.0M | $0 | $0 | 10-K 2026-03-10 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-07-28 |
| Latest annual report | 10-K | 2026-03-10 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 594 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -5.8% |
| 1 month | +8.1% |
| 3 months | -43.3% |
| Year to date | +162.3% |
| 1 year | +294.1% |
| From 52-week high | -59.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| LFCR | Lifecore Biomedical Inc. | $6.42 | -0.08% | $243.2M |
| CAMP | CAMP4 Therapeutics Corporation | $3.86 | +1.58% | $242.2M |
| RCKT | Rocket Pharmaceuticals Inc. | $2.16 | -6.09% | $241.2M |
| BIOA | BioAge Labs Inc. | $5.22 | -5.95% | $239.9M |
| FTH | Faeth Therapeutics Inc. | $9.28 | -7.48% | $239.8M |
| ARCT | Arcturus Therapeutics Holdings Inc. | $8.31 | -0.60% | $239.5M |
| TTRX | Turn Therapeutics Inc. | $8.55 | -8.51% | $261.4M |
| INO | Inovio Pharmaceuticals Inc. | $1.40 | -2.10% | $262.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier